

09771703 091202

In re Patent Application of

LUCAS et al.

Serial No. 09/779,703

Filed: February 9, 2001

Title: TNF-DERIVED PEPTIDES FOR USE IN TREATING OEDEMA

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**RESPONSE/AMENDMENT/LETTER**

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

**Fees are attached as calculated below:**

|  |    |                      |   |            |
|--|----|----------------------|---|------------|
| Total effective claims after amendment | 0  | minus highest number |   |            |
| previously paid for                    | 20 | (at least 20) =      | 0 | x \$ 18.00 |
|  |    |                      |   | \$ 0.00    |

|                                    |   |                      |   |            |
|------------------------------------|---|----------------------|---|------------|
| Independent claims after amendment | 0 | minus highest number |   |            |
| previously paid for                | 3 | (at least 3) =       | 0 | x \$ 84.00 |
|                                    |   |                      |   | \$ 0.00    |

|  |  |    |      |
|--|--|----|------|
| If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper) |  | \$ | 0.00 |
|--|--|----|------|

|  |  |    |      |
|--|--|----|------|
| Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months) |  | \$ | 0.00 |
|--|--|----|------|

|   |  |    |      |
|---|--|----|------|
| Terminal disclaimer enclosed, add \$ 110.00 |  | \$ | 0.00 |
|---|--|----|------|

|   |  |    |      |
|---|--|----|------|
| <input type="checkbox"/> First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00) |  | \$ | 0.00 |
| <input type="checkbox"/> Please enter the previously unentered , filed  |  |    |      |
| <input type="checkbox"/> Submission attached  |  |    |      |

|                 |    |      |
|-----------------|----|------|
| <b>Subtotal</b> | \$ | 0.00 |
|-----------------|----|------|

|  |  |     |      |
|--|--|-----|------|
| If "small entity," then enter half (1/2) of subtotal and subtract  |  | -\$ | 0.00 |
| <input type="checkbox"/> Applicant claims "small entity" status. <input type="checkbox"/> Statement filed herewith |  |     |      |

|  |  |    |      |
|--|--|----|------|
| Rule 56 Information Disclosure Statement Filing Fee (\$180.00) |  | \$ | 0.00 |
|--|--|----|------|

|                                    |  |    |      |
|------------------------------------|--|----|------|
| Assignment Recording Fee (\$40.00) |  | \$ | 0.00 |
|------------------------------------|--|----|------|

|   |  |      |
|---|--|------|
| Other: Amendment; Abstract (separate page); Copy of Notice to File Corrected Application Papers dated July 25, 2002; Copy of Post Card Receipt dated February 9, 2001; Letter and Paper copy of Sequence Listing dated February 9, 2001 |  | 0.00 |
|---|--|------|

|                           |    |      |
|---------------------------|----|------|
| <b>TOTAL FEE ENCLOSED</b> | \$ | 0.00 |
|---------------------------|----|------|

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8<sup>th</sup> Floor  
Arlington, Virginia 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100  
BJS:plb

NIXON & VANDERHYE P.C.  
By Atty: B. J. Sadoff, Reg. No. 36,663

Signature: \_\_\_\_\_



Continuation of  
Serial No.: PCT/EP99/05806 Atty: BJS  
Applicant: Lucas et al Date: 02-09-01  
Title: TN F-Diazine Peptides Client: 2555  
for use in Treating Oedema Ref: 555  
16 Amendment & Amend. claims over 4-8<sup>th</sup> mark up  
10 Pages Specification & claims over 4-8<sup>th</sup> mark up  
2 Claims (zo as amended) pages 4-8  
Sheets Drawings: Formal jc929 U.S. PRO  
Informal 02/779703

Declaration (      ) Pages  
 Assignment  
 Priority Document TDS, PRO-1441<sup>02/09/01</sup> & Transmittal  
 Base Issue Fee Transmittal  
 Fee (Check)

Other: better attacking paper 300  
3 copies  
3 D&G Sequence listing



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
 UNITED STATES PATENT AND TRADEMARK OFFICE  
 WASHINGTON, D.C. 20231  
[www.uspto.gov](http://www.uspto.gov)

| APPLICATION NUMBER | FILING/RECEIPT DATE | FIRST NAMED APPLICANT | ATTORNEY DOCKET NUMBER |
|--------------------|---------------------|-----------------------|------------------------|
| 09/779,703         | 02/09/2001          | Rudolf Lucas          | 2551-55                |

NIXON & VANDERHYE P.C.  
 8th Floor  
 1100 North Glebe Road  
 Arlington, VA 22201



CONFIRMATION NO. 6732  
**FORMALITIES LETTER**  
  
 \*OC00000008519198\*

Date Mailed: 07/25/2002

**NOTICE TO FILE CORRECTED APPLICATION PAPERS*****Filing Date Granted***

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

The required item(s) identified below must be timely submitted to avoid abandonment:

- An abstract was not provided for this application. An abstract of the technical disclosure is required under 37 CFR 1.72(b).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

**For questions regarding compliance to these requirements, please contact:**

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

---

*A copy of this notice **MUST** be returned with the reply.*

*de*  
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY